We are live on ! Find out more
GTBP icon

GT Biopharma
GTBP

53 hedge funds and large institutions have $16.7M invested in GT Biopharma in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 23 increasing their positions, 6 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

283% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 6

40% more call options, than puts

Call options by funds: $334K | Put options by funds: $239K

0.08% more ownership

Funds ownership: 0.52% → 0.6% (+0.08%)

0% more funds holding

Funds holding: 53 → 53 (0)

0% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 11

48% less capital invested

Capital invested by funds: $32.1M → $16.7M (-$15.4M)

Holders
53
Holders Change
–
Holders Change %
0%
% of All Funds
0.82%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
23
Reduced
6
Closed
11
Calls
$334K
Puts
$239K
Net Calls
+$95K
Net Calls Change
+$467K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$1.21M
2
Renaissance Technologies
Renaissance Technologies
New York
+$1.11M
3
Morgan Stanley
Morgan Stanley
New York
+$950K
4
Two Sigma Advisers
Two Sigma Advisers
New York
+$343K
5
State Street
State Street
Massachusetts
+$272K

Top Sellers

Rank Fund Capital Flow
1
SCP
Silverleafe Capital Partners
Tennessee
-$708K
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$416K
3
Millennium Management
Millennium Management
New York
-$230K
4
CSS
Cubist Systematic Strategies
Connecticut
-$227K
5
Geode Capital Management
Geode Capital Management
Massachusetts
-$181K
Name Holding Trade Value Shares
Change 		Change in
Stake
RhumbLine Advisers
26
RhumbLine Advisers
Massachusetts
$51K – – –
Ameriprise
27
Ameriprise
Minnesota
$44K +$72.7K +486 New
Deutsche Bank
28
Deutsche Bank
Germany
$37K +$2.84K +19 +5%
Citadel Advisors
29
Citadel Advisors
Florida
$35K -$13.5K -90 -19%
UBS Group
30
UBS Group
Switzerland
$34K +$33.2K +222 +140%
BJL
31
Brighton Jones LLC
Washington
$34K +$56.3K +376 New
Squarepoint
32
Squarepoint
New York
$33K +$53.7K +359 New
Commonwealth Equity Services
33
Commonwealth Equity Services
Massachusetts
$33K +$55.1K +368 New
Wells Fargo
34
Wells Fargo
California
$32K +$44.3K +296 +502%
WG
35
Welch Group
Alabama
$31K – – –
California State Teachers Retirement System (CalSTRS)
36
California State Teachers Retirement System (CalSTRS)
California
$30K +$599 +4 +1%
AIG
37
American International Group
New York
$29K -$1.5K -10 -3%
New York State Common Retirement Fund
38
New York State Common Retirement Fund
New York
$25K -$299 -2 -0.7%
JP Morgan Chase
39
JP Morgan Chase
New York
$21K – – –
Royal Bank of Canada
40
Royal Bank of Canada
Ontario, Canada
$20K +$11.2K +75 +54%
Simplex Trading
41
Simplex Trading
Illinois
$19K +$31.1K +208 +10,400%
Optiver Holding
42
Optiver Holding
Netherlands
$17K – – –
Citigroup
43
Citigroup
New York
$14K +$12.4K +83 +120%
TRCT
44
Tower Research Capital (TRC)
New York
$12K +$2.39K +16 +14%
AIP
45
Ameritas Investment Partners
Nebraska
$6K – – –
Legal & General Group
46
Legal & General Group
United Kingdom
$6K – – –
Osaic Holdings
47
Osaic Holdings
Arizona
$6K – – –
Rockefeller Capital Management
48
Rockefeller Capital Management
New York
$5K – – –
IAG
49
Investmark Advisory Group
Connecticut
$4K +$7.18K +48 New
TF
50
TimeScale Financial
Massachusetts
$2K – – –
1
2
3

GTBP Hedge Fund Activity: Q4 2021 in Review

53 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q4 2021, worth a combined $16.7M — down 48% from $32.1M a quarter earlier.

Fund positioning in GTBP was balanced in Q4 2021: 11 funds opened new positions, 11 closed out, 23 added to existing stakes and 6 trimmed.

The largest buyer was Vanguard Group, adding an estimated $1.21M. The largest seller was Silverleafe Capital Partners, exiting entirely with an estimated $708K sold.

  • 53 institutional investors held GT Biopharma (GTBP) as of Q4 2021, unchanged from Q3 2021.
  • Funds reported $16.7M of GT Biopharma stock for Q4 2021, down 48% quarter-over-quarter.
  • 11 funds opened new GT Biopharma positions in Q4 2021 and 11 closed out, a net change of 0 holders.
  • The largest GT Biopharma buyer in Q4 2021 was Vanguard Group, an estimated $1.21M added.
  • The largest GT Biopharma seller in Q4 2021 was Silverleafe Capital Partners, an estimated $708K sold.

Based on aggregated 13F filings for Q4 2021.